- Home
- EWTX vs FRME Comparison
EWTX vs FRME Comparison
Compare EWTX & FRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- FRME
- Stock Information
- Founded
- EWTX 2017
- FRME 1893
- Country
- EWTX United States
- FRME United States
- Employees
- EWTX N/A
- FRME N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- FRME Major Banks
- Sector
- EWTX Health Care
- FRME Finance
- Exchange
- EWTX Nasdaq
- FRME Nasdaq
- Market Cap
- EWTX 2.3B
- FRME 2.4B
- IPO Year
- EWTX 2021
- FRME N/A
- Fundamental
- Price
- EWTX $20.13
- FRME $40.19
- Analyst Decision
- EWTX Buy
- FRME Buy
- Analyst Count
- EWTX 8
- FRME 5
- Target Price
- EWTX $45.38
- FRME $47.50
- AVG Volume (30 Days)
- EWTX 1.5M
- FRME 344.2K
- Earning Date
- EWTX 03-03-2025
- FRME 04-24-2025
- Dividend Yield
- EWTX N/A
- FRME 3.48%
- EPS Growth
- EWTX N/A
- FRME N/A
- EPS
- EWTX N/A
- FRME 3.41
- Revenue
- EWTX N/A
- FRME $610,994,000.00
- Revenue This Year
- EWTX N/A
- FRME $17.27
- Revenue Next Year
- EWTX N/A
- FRME $3.93
- P/E Ratio
- EWTX N/A
- FRME $11.86
- Revenue Growth
- EWTX N/A
- FRME N/A
- 52 Week Low
- EWTX $14.90
- FRME $30.55
- 52 Week High
- EWTX $38.12
- FRME $46.13
- Technical
- Relative Strength Index (RSI)
- EWTX 28.86
- FRME 42.16
- Support Level
- EWTX $21.58
- FRME $39.92
- Resistance Level
- EWTX $25.36
- FRME $41.89
- Average True Range (ATR)
- EWTX 1.99
- FRME 0.83
- MACD
- EWTX -0.38
- FRME 0.05
- Stochastic Oscillator
- EWTX 2.67
- FRME 41.18
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.